Changchang Jia

5PUBLICATIONS
6CO-AUTHORS
ChemotherapyCancer cell biologyMedical devicesPredictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jul 11, 2026
PDLIM4 increases sphingolipid accumulation to promote cancer stem cell characteristics and chemotherapy resistance in colorectal cancer.

|Sep 12, 2024
TFCP2L1 drives stemness and enhances their resistance to Sorafenib treatment by modulating the NANOG/STAT3 pathway in hepatocellular carcinoma.

Dongbo Qiu, Tiantian Wang, Yi Xiong

|Apr 19, 2024
RAMP1 Protects Hepatocytes against Ischemia-reperfusion Injury by Inhibiting the ERK/YAP Pathway.

Yongsheng Tang, Zenan Yuan, Xu Lu

|Sep 23, 2022
PROZ Associated with Sorafenib Sensitivity May Serve as a Potential Target to Enhance the Efficacy of Combined Immunotherapy for Hepatocellular Carcinoma.

Yinkui Chen, Xiusheng Qiu, Donghao Wu

|Jul 16, 2020
circNFATC3 sponges miR-548I acts as a ceRNA to protect NFATC3 itself and suppressed hepatocellular carcinoma progression.

Changchang Jia, Zhicheng Yao, Zexiao Lin

Pageof 1

Frequent Collaborators

1 joint publications

Zhicheng Yao

1 joint publications

Zexiao Lin

1 joint publications

Qi Zhang

1 joint publications

Hua Li